#startupoftheday 133- Pathkits Healthcare Pvt Ltd
10 March 2022 | Features
Detect Right, Defeat Disease
Inception- 2020
Location- Gurugram
Domain- Medtech/ Diagnostics
Founders- Amit Gupta, Sunil Goyal, Dr Amit Verma
Total team strength- NA
Total funds raised- Rs 10 crore investment
Investors- MetaDesign Solutions, Molecular Quest
Revenue generated since inception- Rs 50+ crore
Key highlights-
- Into manufacturing Diagnostic Kits, Reagents, and Medical Equipment
- The sister company of MetaDesign Solutions, an IT company that supports Pathkits by way of developing innovative ideas for use of Advance technology in Pharma Industry
- The sister company of Molecular Quest which is NABL certified diagnostic lab and has supported Pathkits in Research & Development
- Products are ICMR approved
- A special focus on direct-to-home diagnostic kits and medical equipment
- Working in the Facility owned by Parent Company MetaDesign
- Out of the total Investment of Rs 10 crore, Rs 2 crore has invested in Land & Buildings
- Total investment in Machinery is of Rs 3 Crore, for enhancing Production Capacity
- Invested Rs 1 Crore in Licenses
- Also invested Rs 4 Crore in Marketing, Raw Material, Human Resources, Softwares, Liasoning, Research
- Currently license to manufacture 20+ products and having 40+ products that the startup is actively working on and which are in several stages for approval
-
Current Products include VTM Kits, VLTM Kits, MTM Kits, UTM Kits, COvid-19 AG Test Kit, RT-PCR Kits, RNA Extraction Kit, RNA, Antigen, Spin Column, Swabs, Pregnancy Kits, Liquid Cytology Kits, Dengue Kits
Future Products include Rapid Diagnostic Kits for Silicosis, Cardiac Markers and Cancer Markers, RT PCR LAMP Kits, Smart Devices and HometestingKits
- Expecting a revenue of Rs 115 Cr in the current year
- Targeting to develop 200+ Medical Diagnostic Kits , 60 approvals every year, in next 5 years
- Planning to export worldwide after getting USFDA, EU, CE and WHO approvals
Founders speak-
"The global In vitro Diagnostics Market is projected to grow from $96.87 billion in 2021 to $149.03 billion in 2028 at a CAGR of 6.3% during forecast period. The fact that reagents are an essential component of every in vitro diagnostic test has contributed to the segment's rise. High economic growth and growing outsourcing to emerging countries offer considerable growth potential for industry players. The instruments category is expected to expand at the fastest CAGR throughout the projection period, owing to key companies' increased focus on releasing new instruments. It is expected the maximum growth for consumption of diagnostic kits would be in developing countries such as India."
- Amit Gupta, Sunil Goyal, Dr Amit Verma- Pathkits Healthcare Team
